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COMPARISON OF TRADITIONAL MULTIVARIABLE LOGISTIC
REGRESSION AND PROPENSITY SCORE APPROACHES FOR
CONTROLLING FOR TREATMENT SELECTION BIAS USING
MONTE CARLO SIMULATION
Wang J, Wu Y, Irish WD
RTI Health Solutions, Research Triangle Park, NC, USA
OBJECTIVES: In the absence of well-controlled clinical studies,
medical records provide a potential wealth of information about
the value of treatments; however, differences in pretreatment
patient or other characteristics may inﬂuence treatment assign-
ment and lead to biased estimates of treatment effects. Several
strategies are available to reduce treatment selection bias. These
include multivariable regression (MR) and propensity score 
(PS) techniques. Cepeda and colleagues (Am J Epidemiol
2003;158:280–7) demonstrated that PS is less biased than MR
when the ratio of number of events to number of confounders
(REC) is less than 8 by simulation. Using methods deemed more
appropriate than Cepeda, we set out to evaluate conditions upon
which their conclusions may be incorrect. METHODS: Monte
Carlo simulation was performed in which each subject: 1) had
10 confounders (Zk : k = 1, . . . , 10) generated using normal and
Bernoulli distributions; 2) was assigned to exposure or non-
exposure with probability p determined by confounding vari-
ables; and 3) was given a binary response variable with
probability g determined by confounder and exposure strength
of association. For each simulation, binary logistic regression
was used to: 1) generate individual PSs by regressing exposure
variable on the confounder variables Z; and 2) estimate PS- and
MR-adjusted treatment effects. Process was repeated 1000 times
to evaluate bias and power of the statistical test. RESULTS: MR
method produces asymptotically unbiased estimate of treatment
effect; a result that is only marginally affected by the REC. Even
when REC was 4.5, MR produced unbiased estimate of treatment
effect with larger sample size. Contrary to the MR method, PS
produces estimates that are consistently lower than the true effect
regardless of sample size or REC. Power is always lower using the
PS method. CONCLUSION: Results suggest PS method provides
no statistical advantage over traditional MR; a conclusion that
is contrary to Cepeda et al recommendations.
MC3
CONTROLLING FOR COMORBIDITIES USING VARIATIONS OF
THE CHARLSON COMORBIDITY INDEX ON MEDICARE
CLAIMS DATA:THE CASE OF OVERACTIVE BLADDER
Cisternas MG, Foreman AJ, Miller DP
Ovation Research Group, San Francisco, CA, USA
OBJECTIVES: To compare variants of the Deyo-modiﬁed Charl-
son Comorbidity Index (DM-CCI) as comorbidity adjustors
when predicting annual health care costs attributable to a spe-
ciﬁc condition using administrative data. METHODS: We
extracted all medical claims for Medicare individuals >65 with
continuous coverage for Medicare parts A and B (N = 1.2
million) during 2003 and 2004 from ﬁles obtained from the
Centers for Medicare and Medicaid Services. In order to estimate
annual expenditures attributable to overactive bladder (OAB),
we used multiple regression techniques that adjusted for demo-
graphics (age, race, region, gender) and comorbidities. Comor-
bidities were deﬁned in four ways. Method 1 used the DM-CCI
as the only measure of comorbidity. Method 2 used the DM-CCI
plus indicator variables for other conditions not included in the
DM-CCI that were not considered sequelae of OAB (hyper-
lipidemia, depression/anxiety, hypertension, heart disease,
osteoarthritis, cataracts/glaucoma, enlarged prostate, muscu-
loskeletal conditions excluding arthritis, GERD, and neurologi-
cal conditions). Model 3 was identical to Model 2 but excluded
depression/anxiety. Model 4 was identical to Model 2 but also
included events and conditions related to OAB (UTIs, skin in-
fections, falls/fractures, and vulvovaginitis). RESULTS: Mean
annual expenditures attributable to OAB were $2278, $825,
$996, and $94 per individual with OAB for Models 1, 2, 3, and
4 respectively. CONCLUSION: Attributable costs calculations
using regression techniques may be very sensitive to the speciﬁ-
cation of comorbid conditions. Analysts need to avoid both the
omission of key confounders, which can overstate the cost of a
condition (e.g., Model 1), and over-speciﬁcation, which will
understate the cost of a condition by attributing too much cost
to comorbidities that are actually related to the condition of
interest (e.g., Model 4). Candidate comorbid conditions must be
considered carefully before they are included in regression
models to predict condition-speciﬁc attributable costs.
MC4
TIME HORIZON BIAS IN ECONOMIC EVALUATIONS
Sander B1, Krahn MD2
1University of Toronto,Toronto, ON, Canada, 2University Health
Network,Toronto, ON, Canada
OBJECTIVES: To systematically evaluate the impact of time
horizon choice on the incremental cost-effectiveness ratio (ICER)
under varying assumptions regarding treatment effectiveness,
costs and discount rate. METHODS: We developed a Markov
model, comparing two hypothetical strategies and predicting
marginal quality adjusted life years (QALYs), costs and ICERs
as a function of time horizon (ranging from 5 to 50 years). We
assume that clinical trial data is available for 5 years of follow
up. The model was analyzed for the following scenarios: extrap-
olation of survival beneﬁt (optimistic, intermediate, conserva-
tive), prediction of treatment costs (one time costs only, constant
continued incremental cost with/without cost decrease after 10
years), and discount rate (undiscounted, same discount rate for
QALYs and costs, differential discount rate for QALYs and
costs). RESULTS: The effect on ICER is greatest when compar-
ing a 5 year to a 10 year or longer time horizons. For most sce-
narios the ICER does not change much when extending the time
horizon beyond 15 years (less than 20% relative change in
ICER).The choice of time horizon conditional on the extrapola-
tion method of survival beneﬁt (optimistic and intermediate sce-
narios) for one time cost scenarios had the greatest impact on
reducing the ICER (reduction of >60% if using 10 year instead
of 5 year time horizon). In scenarios with continued costs, the
ICER was sensitive to a cost decrease after 10 years but less sen-
sitive to the discount rate. CONCLUSION: Current guidelines
suggest adopting a lifetime time horizon when a mortality beneﬁt
is present. Our study measures the bias associated with adopt-
ing the time horizon of a clinical trial, a common practice. Most
susceptible to bias are scenarios with one time costs as the ICER
is most sensitive to the chosen extrapolation method for survival
beneﬁts. The choice of time horizon and its impact on ICER
warrant careful consideration.
PODIUM SESSION II: NEUROLOGY
NE1
EMPLOYEES WITH FIBROMYALGIA: MEDICAL COMORBIDITY,
HEALTH CARE COSTS,AND WORK LOSS
White LA1, Birnbaum HG PhD1, Kaltenboeck A1,Tang J1, Mallett D2,
Robinson R3
1Analysis Group, Inc., Boston, MA, USA, 2Ingenix, Inc., Rocky Hill, CT,
USA, 3Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: To compare health care use, health care costs,
and work loss costs in employees with ﬁbromyalgia (FM) to
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matched samples of employees with osteoarthritis (OA) and non-
FM controls. METHODS: Samples were selected from a U.S.
claims database of privately insured beneﬁciaries. Employees in
the FM sample had ≥2 ﬁbromyalgia diagnoses in 1999–2005
(with ≥1 in 2002–2005) and were continuously enrolled in 2005.
Controls and employees with OA had no FM claims and were
matched to the study sample on age, gender, and region. Costs
are reported for 2005 experience. Nonparametric Wilcoxon tests
were used to determine statistically signiﬁcant differences in
skewed variables including costs. Chi-square tests were used to
test for differences in for categorical variables. RESULTS: Mean
age in the FM sample was 50.1 years and 51.6% were female.
Compared to control and OA samples, employees with FM had
higher rates of depression, anxiety, chronic fatigue syndrome,
and many pain diagnoses. The FM sample used more medical
care overall, especially emergency department visits, specialty
physician visits, and prescriptions. Direct (medical and prescrip-
tion drug) costs in the FM sample were signiﬁcantly higher 
than control sample costs ($7286 vs. $3915, p < 0.0001), and
approached OA sample costs ($7286 vs. $8325, p = 0.3758).
Prescription costs comprised a relatively large proportion of total
FM costs; prescription cost levels were comparable to employ-
ees with OA ($1630 vs. $1341, p < 0.3541) and signiﬁcantly
higher than controls ($1630 vs. $755, p < 0.0001). Work loss
costs in the FM sample ($2913) were signiﬁcantly higher than
those of control ($1359, p < 0.0001) and OA ($2537, p <
0.0001) samples. CONCLUSIONS: Fibromyalgia imposes sig-
niﬁcant economic burden. Average total costs among employees
with ﬁbromyalgia were almost twice those of matched controls
and approximated costs of employees with osteoarthritis. Indi-
rect costs were more than double those of controls and even
exceeded costs of osteoarthritis patients with similar demo-
graphic proﬁles.
NE2
IMPACT OF PATIENT COMORBIDITIES ON
PHARMACOLOGICAL TREATMENT OF INSOMNIA:AN
ANALYSIS OF THE NATIONAL AMBULATORY MEDICAL CARE
SURVEY DATA: 1995–2004
Pawaskar MD, Balkrishnan R
The Ohio State University College of Pharmacy, Columbus, OH, USA
OBJECTIVES: Patients with insomnia are likely to have comor-
bidities that could affect treatment options. Hence the objective
of this study was to examine the prevalence of comorbidities and
their impact on the pharmacological treatment of insomnia in
US primary care settings. METHODS: A retrospective data
analysis of the National Ambulatory Medical Care Survey from
1995 to 2004 was performed. Patients aged ≥18 years, who had
a physician visit with a diagnosis of insomnia in US outpatient
settings were included in this study. Ofﬁce visits of patients with
primary or secondary insomnia/sleep complaints and resultant
diagnoses were included in the analysis. Data were stratiﬁed
according to patient characteristics, physician specialty, resulting
diagnosis and medications prescribed. Multivariate logistic
regression models were used to examine impact on prescribing
pharmacotherapy for insomnia. RESULTS: A total of 5487
unweighted patient visits for insomnia were identiﬁed from the
year 1995–2004, representing 107.4 million patients in the
overall U.S. population. Ofﬁcial visits for insomnia were more
common in females (60.4%), with an increasing prevalence in
older patients. Approximately 41% of the patients with insom-
nia had a concomitant diagnosis of a mental comorbidity with
higher prevalence of anxiety (15.6%) followed by episodic mood
disorders (14.9%) and depression (7%). Patients with mental
comorbidities were 35% less likely to receive pharmacological
treatment for insomnia than those without mental comorbidities
(OR: 0.65, 95% CI: 0.51–0.84). Subgroup analysis of type of
mental comorbidity revealed that patients with comorbid anxiety
were 42% less likely to receive pharmacological treatment for
insomnia than those without anxiety (OR: 0.58, 95% CI:
0.45–0.73). CONCLUSION: Mental comorbidities such as
episodic mood disorder, anxiety, and depression are prevalent in
patients with insomnia and affect receipt of pharmacological
therapy for insomnia. Health care professionals should consider
the impact of mental comorbidities while treating patients with
sleep difﬁculties.
NE3
THE IMPORTANCE OF MODIFYING THE COURSE OF
ALZHEIMER’S DISEASE: OLDER AMERICANS’ RISK-BENEFIT
PREFERENCES FOR NEW TREATMENTS
Mohamed AF1, Johnson FR1, Hauber B2, Leibman C3,Arrighi HM3
1Research Triangle Institute, Research Triangle Park, NC, USA,
2Research Triangle Institute, Doylestown, PA, USA,
3Elan Pharmaceuticals, Inc, San Diego, CA, USA
OBJECTIVES: The objective of this study is to quantify the
strength of preferences of older Americans for possible
Alzheimer’s disease (AD) treatment beneﬁts by estimating their
willingness to accept the risk of death or severe disability in
exchange for modifying the course of AD. Currently, AD has no
cure. A breakthrough in treatment that modiﬁes the underlying
AD disease process would be a major achievement with enor-
mous medical and social beneﬁts. Little is known concerning
older Americans’ perceptions about AD and their willingness to
accept risk to avoid AD. METHODS: American residents aged
60 years and older who have not been diagnosed with AD, and
are not taking prescription medicines to treat AD, memory prob-
lems or dementia completed an online survey questionnaire that
included a series of stated-choice trade-off tasks. Respondents
chose between pairs of hypothetical treatment alternatives, each
including different 7-year AD disease-progression proﬁles and
risks of serious adverse events that would result in death or
severe disability. We used mixed-logit methods to estimate the
maximum acceptable risk (MAR) of serious adverse events that
would result in death or severe disability. RESULTS: 2146
respondents completed the survey. Mean (SD) age was 70 (7.4).
In return for preventing AD from progressing beyond the mild
stage, the mean MAR (95% CI) was 46.8% (40.3%–54.3%);
that is older Americans were willing, on average, to accept an
increase in the risk of death or severe disability from stroke of
nearly 50% to avoid progression to the moderate and severe
stages of AD. CONCLUSION: Older Americans’ willingness to
accept signiﬁcant increases in the risk of death or disability in
exchange for treatments that modify the course of AD indicates
the value of such treatment beneﬁts.
NE4
COST-UTILITY ANALYSIS EVALUATING LIDOCAINE 5%
MEDICATED PLASTER RELATIVE TO GABAPENTIN FOR POST-
HERPETIC NEURALGIA IN SCOTLAND
Dakin HA1, Nuijten MJC2, Liedgens H3, Poulsen Nautrup B3
1Abacus International, Bicester, Oxfordshire, UK, 2Erasmus University,
Rotterdam,The Netherlands, 3Grünenthal GmbH, Aachen, Germany
OBJECTIVES: To assess the cost-effectiveness of using a lido-
caine 5% medicated plaster (lidocaine plaster) in the treatment
of post-herpetic neuralgia (PHN) in place of gabapentin from the
perspective of the Scottish National Health Service. METHODS:
A Markov model was constructed in TreeAge to calculate the
costs and beneﬁts of gabapentin and lidocaine plaster when used
in primary care over a six-month time horizon in patients with
